At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)
In Brief
A Phase 2 clinical trial evaluating Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, and 3 other interventions for DS Stage I Plasma Cell Myeloma and 3 related conditions. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill more cancer cells.
Study Details
Timeline
Interventions
Undergo autologous stem cell transplant
Undergo autologous stem cell transplant
Given IV
Correlative studies
Given IV